KAT6B

Across TCGA pan-cancer cohorts, KAT6B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KAT6B data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KAT6B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KAT6B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, GBM, and PDAC are the cancer types where KAT6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.254	0.909	.006	17	view →
GBM	OS	Quartile	All	1.000	0.258	.024	6	view →
PDAC	OS	Quartile	All	0.604	1.000	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KAT6B–LUAD (DFS)

Open the LUAD breakdown →